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Abstract
The multifactor dimensionality reduction (MDR) is a model-free approach that can identify gene ×
gene or gene × environment effects in a case-control study. Here we explore several modifications
of the MDR method. We extended MDR to provide model selection without crossvalidation, and
use a chi-square statistic as an alternative to prediction error (PE). We also modified the
permutation test to provide different levels of stringency. The extended MDR (EMDR) includes
three permutation tests (fixed, non-fixed, and omnibus) to obtain p-values of multilocus models.
The goal of this study was to compare the different approaches implemented in the EMDR method
and evaluate the ability to identify genetic effects in the Genetic Analysis Workshop 14 simulated
data. We used three replicates from the simulated family data, generating matched pairs from family
triads. The results showed: 1) chi-square and PE statistics give nearly consistent results; 2) results
of EMDR without cross-validation matched that of EMDR with 10-fold cross-validation; 3) the fixed
permutation test reports false-positive results in data from loci unrelated to the disease, but the
non-fixed and omnibus permutation tests perform well in preventing false positives, with the
omnibus test being the most conservative. We conclude that the non-cross-validation test can
provide accurate results with the advantage of high efficiency compared to 10-cross-validation, and
the non-fixed permutation test provides a good compromise between power and false-positive
rate.
Background
Gene × gene and gene × environment interactions
undoubtedly play an important role in risk of complex
diseases. These interactive effects, particularly when there
are weak marginal effects, may be difficult to detect with
traditional analysis approaches. Though classic statistical
methods (e.g., logistical regression) are commonly used,
as the number of possible interactions increases, the
number of interaction terms grows exponentially with the
addition of the main effect of each gene, leading to over-
parameterization and low power in models with high-
dimensionality [1]. To address this concern, the multifac-
tor dimensionality reduction (MDR) was developed to
identify interactions among multiple factors, which
together influence disease susceptibility [2].
The MDR method was inspired by the combinatorial par-
titioning (CP) method, which builds models using data-
driven methods [3]. In contrast to CP, MDR always
reduces the dimensionality to two partitions, high risk
and low risk. By applying the technique of n-1 crossvali-
dation (keeping n-1 groups for training and leaving out
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one group for validation), MDR identifies the best model
with maximum consistency and minimum prediction
error. To evaluate whether the best model is statistically
significant, a permutation test based on data simulation is
applied to obtain a p-value. Though the MDR has been
shown to provide a powerful approach [4], it does have
some limitations. First, the MDR uses prediction error as
an estimate of the internal validity of the selected model.
Prediction error represents the percentage of misclassifica-
tion error in the test dataset. Theoretically, the smaller the
prediction error is, the better the model is at predicting
disease status. However, in real data analysis of complex
diseases, significant models often have relatively high pre-
diction error, typically greater than 40%. This is a particu-
lar problem when risk alleles are common. A second
difficulty is that the MDR ideally determines the best
model with maximum consistency and minimum predic-
tion error. But in real analysis, consistency and prediction
error often conflict. We have experienced this in our anal-
ysis of real data, where, using 10-fold cross-validation, a
model with consistency as high as 9 may have prediction
error much higher than a model with consistency of only
1. Finally, the MDR permutation test simultaneously
assesses significance over all combinations of marker loci
evaluated (i.e., complete permutation test, discussed
below), which is powerful in decreasing type I error, but
can lead to a severe loss in power.
To address these limitations, we have extended the MDR
in several ways (EMDR, as we refer to it). The EMDR pro-
vides both a chi-square statistic and prediction error with
or without 10-fold cross-validation for selection of the
best model. Three permutation tests are provided to
obtain the p-value, based on different hypotheses. We
used the Genetic Analysis Workshop 14 (GAW14) simu-
lated data, specifically targeting regions with known inter-
actions (based on knowledge of the answers), to evaluate
the novel features of EMDR and compare it with the orig-
inal MDR.
Methods
Dataset
The dataset used for validation of the EMDR was the sim-
ulated GAW14 data of Kofendrerd Personality Disorder
(KPD). The broadest phenotype, P3, was selected for this
study. We selected the first qualifying family triad (2 par-
ents and 1 affected offspring) from each pedigree in the
simulated family dataset. To provide an adequate sample
size we pooled replicates 1–3 for a total of 440 independ-
ent triads.
We consulted the answers to target our exploration of
multilocus effects to specific loci. The answers revealed
that there are 2-way interactions involving 4 loci affecting
risk for P3 (D1–D4 and D2–D3). We considered several
sets of markers (Table 1) to explore the properties of the
EMDR. Due to computational limitations, we restricted
the size of each marker set to 8 markers. Data I contain 8
independent markers unlinked to any of the disease loci
on chromosome 2. In Data II, 8 markers were selected sur-
rounding disease loci D1 and D4. Similarly, 8 markers in
Data III surround disease loci D2 and D3 (Table 1).
Statistics
The EMDR, like MDR, develops a locus model to predict
affection status, grouping genotypes into high- and low-
risk classes. The 10-fold cross-validation test of EMDR
divides the dataset into 10 training datasets (each with
90% of the sample), which are used to train the locus
model, and 10 test datasets (each with the remaining 10%
of the sample), which are used to validate the locus model
[5]. Ten-fold cross-validation can output at most 10 differ-
ent locus models from which the best model is selected
based on statistics computed in the test dataset. Two sta-
tistics are computed for each model: chi-square and pre-
diction error (PE). PE is calculated as the proportion of
cases and controls that are misclassified by the model. The
chi-square statistic measures the association between gen-
Table 1: Marker description of data I, II and III
Data I Data II Data III
Marker Index Marker Name Marker Name Loci Marker Name Loci
1 C02R0092 C01R0052a D1 B03T3064
2 C02R0105 B01T0561 D1 B03T3065
3 C02R0118 B01T0562 B03T3066
4 C02R0131 B01T0563 B03T3067 D2
5 C02R0144 B09T8335 B05T4135
6 C02R0157 C09R0765 D4 B05T4136 D3
7 C02R0170 B09T8337 D4 C05R0380 D3
8 C02R0183 B09T8338 B05T4138
a Bold text indicate that p-values of the statistics are significant at alpha = 0.05.BMC Genetics 2005, 6:S145
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otype (high-risk and low-risk group) and affection status
(case and control group) in a two-way table. It is calcu-
lated as sum of the square of the differences between the
observed and expected frequency in each cell, divided by
the expected value, across all of the cells in the table:
. The identification of the
best model is based on the value of chi-square or PE. It is
possible in a 10-cross-validation EMDR run to generate
two different best models in terms of largest chi-square or
smallest PE.
Assessing statistical significance of a model depends on a
p-value from a permutation test. A model with a p-value <
0.05 is regarded as a significant multilocus effect in our
analyses. EMDR provides three types of permutation tests
in which each adjusts for the data reduction technique
across locus combinations to a different extent. All permu-
tation tests hypothesize that a specific n-locus genotype
model is independent of disease status. To identify the
locus model, matched pairs from the GAW14 simulated
data were constructed by deriving transmitted and non-
transmitted alleles from independent family triads (par-
ents and an affected child), where the case genotype is the
transmitted pair of alleles and the pseudocontrol is the
nontransmitted pair. The simulated data for the permuta-
tion test are generated by permuting the status of case and
control within each pair (e.g., for a family triad transmit-
ted and nontransmitted genotypes are permuted ran-
domly). The fixed permutation test considers only the
specific best n-locus model (e.g., suppose loci 1 and 2 are
selected for the 2-locus model). The exact same set of loci
is then evaluated in the permuted dataset, redefining
high- and low-risk genotype classes and recomputing the
statistic (PE, chi-square) for that model. After conducting
the procedure a large number of times (e.g., 1,000 times),
we compared the observed statistic to the distribution of
permuted statistics to obtain the p-value.
The non-fixed and the omnibus permutation tests are
more computationally intensive. Suppose the total
number of markers or loci in dataset is m. To compute the
p-value of a specific n-locus model, the non-fixed permu-
tation test computes the statistic in the permuted data
considering all possible n-locus models (i.e., all m!/ [(m-
n)!*n!] models). In the omnibus permutation test, the
statistic is selected from the entire set of models, i.e., all 1-
locus, 2-locus, ..., k-locus models (i.e., all
 models). For bi-allelic loci, the
() χ2 =
− ∑
(e x p )
exp
observed ected
ected
2
mm i i i
k !/(( )! !) −∗ = ∑ 1
Table 2: non-crossvalidation analysis of data I
p-Value of chi square p-Value of prediction error
Model χ2 Fixed permutation Non-fixed 
permutation
Prediction error Fixed permutation Non-fixed 
permutation
(8) 1.939 0.284 >0.284 0.4773 0.198 >0.198
(4 8) 7.099 0.05a 0.592 0.4557 0.024 0.363
(2 7 8) 12.49 0.228 >0.228 0.4409 0.207 >0.207
a Bold text indicate that markers flanking or located at simulated disease loci.
Table 3: Analysis of data II
p-Value of chi square p-Value of prediction error
Marker χ2 Fixed 
permutation
Non-fixed 
permutation
Prediction 
error of test 
data
Fixed 
permutation
Non-fixed 
permutation
Omnibus 
permutation
10-fold cross-validation
(6) 1.446 0.136 0.572 0.462 0.018a 0.13 0.184
(6 7) 3.101 0.002 0.046 0.462 00 . 0 1 0.184
(2 3 8) 2.284 0.027 0.094 0.432 0 0.008 0.043
Non-cross-validation
(6) 6.630 0.03 0.186 0.458 0.017 0.138
(6 7) 20.985 0 0.006 0.430 00 . 0 1 9
(2 3 8) 39.324 0 0.005 0.394 00 . 0 0 3
a Bold text indicate that p-values of the statistics are significant at alpha = 0.05.BMC Genetics 2005, 6:S145
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value of k, the largest number allowed for testing, follows
the formula: j/3k>3 (j is the size of the test dataset in 10-
fold cross-validation).
Results
Unlinked loci
Data I (markers unlinked to disease loci) was first ana-
lyzed by the EMDR to evaluate false-positive rates. For
non-cross-validation, the non-fixed permutation test did
not detect any significant models (Table 2). In contrast,
the fixed permutation test yielded significant 2-locus
models (p = 0.05 and 0.02 for chi-square and PE, respec-
tively). The results are similar to 10-fold cross-validation.
As expected, the omnibus test did not give us the signifi-
cant results (data not shown).
D1–D4 multi-locus effects
Data II includes a set of markers flanking loci D1 and D4.
Ten-fold cross-validation and non-cross-validation identi-
fied the same best 1-, 2-, and 3-locus models using both
chi-square and PE test statistics (Table 3). However, the
two markers involved in the best 2-locus model are all
located in D4 region. Only the best 3-locus model
included markers near both D1 and D4. This effect was
identified by all permutation tests except non-fixed per-
mutation test with 10-fold cross-validation.
D2–D3 multi-locus effects
Data III includes markers flanking D2 and D3. Both the
chi-square and PE statistics gave the same 1- and 2-locus
models with and without cross-validation (Table 4).
However, the chi-square statistic displayed a different 3-
locus model from PE. This discrepancy is likely due to
computational differences of the statistics when there are
minor differences between the models. All best models
were significant under fixed and non-fixed permutation
test. However, neither of 2- and 3-locus models include
markers around D2. The omnibus permutation test gave a
significant 3-locus model only.
Table 5 shows models other than the best model that were
also significant with the EMDR. The chi-square and PE
under fixed and non-fixed permutation test detected sig-
nificant 2- and 3-locus models that include markers
around both D2 and D3. This shows that although the
D2–D3 effect was not detected as the best model, it was
successfully identified among significant models.
Table 4: Analysis of data III
p-Value of chi square p-Value of prediction error
Marker χ2 Fixed 
permutation
Non-fixed 
permutation
Prediction 
error of test 
data
Fixed 
permutation
Non-fixed 
permutation
Omnibus 
permutation
10-fold crossvalidation
(6) 2.507 0.006b 0.088 0.444 0.002 0.006 0.255
(6 7) 3.647 0.002 0.016 0.422 00 0.117
(5 6 7) --a -- -- 0.398 00 0 . 0 4 2
(6 7 8) 4.782 0 0.004 -- -- -- --
Non crossvalidation
(6) 13.870 0.001 0.006 0.438 0.001 0.004
(6 7) 35.276 00 0.408 00 . 0 0 2
(5 6 7) -- -- -- 0.384 00
(6 7 8) 49.657 0 0 -- -- --
a --, not tested
b Bold text indicate that p-values of the statistics are significant at alpha = 0.05.
Table 5: D2–D3 effect of data III
p-value of chi-square p-value of prediction error
Model Effect non-cross-
validation non-
fixed permutation
10-fold cross-
validation, non-
fixed permutation
non-cross-
validation, non-
fixed permutation
10-fold cross-
validation, non-
fixed permutation
10-fold cross-
validation, 
omnibus 
permutation
(2 6) D2–D3 0 0.02 0.002 0 0.122
(2 6 7) D2–D3 0 0.028 0 0.002 0.09BMC Genetics 2005, 6:S145
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Discussion
Our analysis of the GAW14 simulated data gives a com-
parison of the traditional MDR and several different
options in the EMDR with the benefit of knowing the
answers. The traditional MDR identifies the best marker
models by 10-fold cross-validation using the PE statistic
and obtains p-values by permutation testing (i.e., omni-
bus permutation in EMDR). Our EMDR extended the
MDR to include a chi-square statistic in addition to PE,
options for 10-fold cross-validation or non-cross-valida-
tion (with PE and chi-square statistics), and multiple per-
mutation tests (fixed, non-fixed, and omnibus). By
comparing these different methods, we found that 10-fold
cross-validation and non-cross-validation were fairly con-
sistent in identification of the best locus-model. The fixed
permutation test produced several false-positive results,
and the omnibus permutation test of the traditional MDR
lost the power to identify the known D1–D4 and D2–D3
interaction. In Data I (unlinked to disease loci), non-
cross-validation with non-fixed permutation test gener-
ated p-values over 0.5 for nearly for all of the best models
(1-, 2- and 3- models) with no false positives. Non-cross-
validation with the non-fixed permutation test also cor-
rectly detected significant marker effects between D1–D4
in Data II and significant marker effects between D2–D3
in Data III, suggesting that non-cross-validation with the
non-fixed permutation test has the power to identify true
multilocus interactions (D1–D4 and D2–D3 interac-
tions). We conclude that non-cross-validation using the
non-fixed permutation test performs well on matched
data from three replicates (440 case/control pairs) from
the GAW14 simulated data.
In the GAW14 simulated data, we found that the model
statistics of the 10-fold cross-validation approach had
large variation, leading to inconsistent conclusions. Small
sample size of the test data and genetic heterogeneity
could cause these inconsistencies, under which non-cross-
validation performs better. Non-cross-validation
improved two limitations of the original MDR (computa-
tional intensity and high dimensionality with small sam-
ple) [6]. Non-cross-validation has the advantage of high
computational efficiency (no validation by test data is
needed), no false-positive results, and was more consist-
ently able to detect true loci compared with the original
10-fold cross-validation approach of the MDR.
Similar to MDR, the EMDR has the power to detect joint
effects of multiple genes on disease risk. However, the
method cannot itself differentiate interactions from main
effects, nor can it distinguish whether a joint effect is
driven by a strong marginal effect. For example, in the
Data II analysis, EMDR identified (6), (2 6), and (2 6 7)
as significant best models, however, it is hard to tell if the
gene × gene effect within (2 6) and (2 6 7) is driven by (6)
only or due to the interaction between D2 and D3. One
possible solution is to use logistic regression to model the
genotype effects. We tested (2 6) model in this study, but
found no interaction between locus 2 and 6 while forcing
all factors into the model, suggesting that the 2-locus
model might be due to the combination effect of inde-
pendent main effects. Interpretation of models developed
by the EMDR in complex genetic diseases is an important
direction for future studies.
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